What Will Happen to MATEON THERAPEUTICS INCORPORATED (OTCMKTS:MATN) Next? The Stock Has Increase in Shorts

December 31, 2017 - By Adrian Mccoy

The stock of MATEON THERAPEUTICS INCORPORATED (OTCMKTS:MATN) registered an increase of 4.29% in short interest. MATN’s total short interest was 7,300 shares in December as published by FINRA. Its up 4.29% from 7,000 shares, reported previously. With 100,000 shares average volume, it will take short sellers 0 days to cover their MATN’s short positions.

The stock increased 22.60% or $0.0271 during the last trading session, reaching $0.1469. About 137,661 shares traded or 79.37% up from the average. Mateon Therapeutics, Inc. (OTCMKTS:MATN) has 0.00% since December 31, 2016 and is . It has underperformed by 16.70% the S&P500.

Mateon Therapeutics, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents for the treatment of cancer in the United States. The company has market cap of $3.90 million. The Company’s principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating neuroendocrine tumors. It currently has negative earnings. The firm also develops OXi4503 that is in Phase I/II clinical trial stage for treating patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes.

More notable recent Mateon Therapeutics, Inc. (OTCMKTS:MATN) news were published by: Globenewswire.com which released: “Mateon Therapeutics Provides Update on its Clinical Trial Programs and Milestones” on June 12, 2017, also Globenewswire.com with their article: “Mateon Therapeutics Receives FDA Fast Track Designation for OXi4503 in …” published on June 07, 2017, Seekingalpha.com published: “OXiGENE: A Frustrating Company That Remains Cheap” on October 06, 2015. More interesting news about Mateon Therapeutics, Inc. (OTCMKTS:MATN) were released by: Globenewswire.com and their article: “Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in …” published on June 28, 2017 as well as Globenewswire.com‘s news article titled: “Mateon Therapeutics Announces Abstract Presentations for the American …” with publication date: March 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.